Pyxis Oncology, Inc. Share Price
NASDAQ: PYXS | Micro CapPyxis Oncology, Inc. Stock Performance
Open $3.32 | Prev. Close $3.31 | Circuit Range N/A |
Day Range $3.21 - $3.35 | Year Range $1.03 - $5.55 | Volume 10,496 |
Average Traded $3.25 |
Pyxis Oncology, Inc. Share Price Today
As of 30 August 2026, Pyxis Oncology, Inc.'s share price is $3.23. The stock opened at $3.32, compared to its previous close of $3.31. During today's trading session, Pyxis Oncology, Inc.'s share price traded between $3.21 and $3.35, with an average price of $3.28. Over the past 52 weeks, the stock has recorded a high of $5.55 and a low of $1.03. In terms of performance, Pyxis Oncology, Inc.'s share price has risen by 118.98% over the last six months and is up 148.46% on a year-on-year basis.
Pyxis Oncology, Inc. Share Price Chart
Pyxis Oncology, Inc. Stock Fundamentals & Key Indicators
Market Cap $200.72M | PE Ratio (TTM) -2.52 | Dividend Yield N/A |
EPS (TTM) $-1.28 | Revenue (TTM) $13.86M | Return On Equity (TTM) -149.08% |
Profit Margin -574.55% | Debt to Equity 0.40 | Quarterly Earnings Growth YoY -3.77% |
Pyxis Oncology, Inc. Quarterly Profit & Loss
All figures in USD
Pyxis Oncology, Inc. Annual Profit & Loss
All figures in USD
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Pyxis Oncology, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.79 | $3.34 | +26.52% |
Jul 2026 | $3.06 | $2.64 | -12.00% |
Jun 2026 | $1.81 | $3.00 | +66.20% |
May 2026 | $1.69 | $1.80 | +5.87% |
Apr 2026 | $1.52 | $1.71 | +16.78% |
Mar 2026 | $1.40 | $1.46 | -1.02% |
Feb 2026 | $1.49 | $1.48 | +1.03% |
Jan 2026 | $1.14 | $1.46 | +26.41% |
Dec 2025 | $5.10 | $1.16 | -77.66% |
Nov 2025 | $3.65 | $5.17 | +44.62% |
Oct 2025 | $2.26 | $3.58 | +61.40% |
Sep 2025 | $1.29 | $2.21 | +70.38% |
PYXS Share Price FAQs
What is Pyxis Oncology, Inc. share price today?
What is the 52 week high and 52 week low of Pyxis Oncology, Inc. stock?
What is PYXS's market capitalisation today?
What is PYXS's net income for the last quarter?
What is the 5 year returns of PYXS?
What is the high & low stock price of PYXS today?
Can I buy PYXS shares in India?